Incidence, Clinical Characteristics and Risk Factors of Late Infection in Solid Organ Transplant Recipients: Data from the RESITRA Study Group

Abstract

4-3), re-operation (OR 1.9; CI 95%: 1.3-2.8) relapsing viral infection apart from CMV (OR 1.9; CI 95%: 1.1-3.5), previous bacterial infection (OR 1.8; CI 95%: 1.2-2.6) and lung transplantation (OR 4.5; CI 95%: 2.6-7.8). Severe LI occurs in a subgroup of high-risk SOT recipients who deserve a more careful follow-up and could benefit from prolonged prophylactic measures similar to that performed in the early period after transplantation.

Modern renal transplantation: present challenges and future prospects

“…It has also been used in association with calcineurin inhibitors in place of antiproliferative drugs. Although the predominant benefit is the reduction of calcineurin toxicity, it has been shown to be superior to CyA and steroids (both with and without azathioprine) in the prevention of acute rejection,27 28 but this was associated with an increased risk of infection 29 30…”

Toll-like receptor signaling in transplantation

“…The incidence and clinical characteristics of infections after solid organ transplantation was described in a retrospective study of 2702 solid organ transplant recipients from the database of the Spanish Network of Infection in Transplantation (RESITRA) [40]. The incidence of infections in the first month after transplantation was observed to be significantly higher (3.5 episodes per 1000 transplant-days) compared to that in the late period (0.4 episodes per 1000 transplantation days), with higher rates of infections following kidney-pancreas, lung and liver allografts (11.52–14.47 episodes per 1000 transplantation days) and lower rates for kidney and heart allografts (4.91–8.78 episodes per 1000 transplantation days).…”

Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort

“…Examples are the Scientific Registry of Transplant Recipients (SRTR) in the US [1, 2], the Heidelberg-based Collaborative Transplant Study (CTS) in Europe [3, 4], the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry [5], as well as the Spanish Resitra cohort [6, 7]. These large registries focus on specific biomedical factors but are often limited in regard to the integration of psychosocial and behavioral factors, infectious disease occurrence, immunologic factors and a variety of long-term outcome.…”

“…The main objectives of the STCS are to:Record all SOTs within one unique database system in order to have a complete assessment of all patient-, transplant-, and center-specific activities in Switzerland.Prospectively collect high quality longitudinal clinical and laboratory data of transplant recipients at the Swiss national level, to evaluate the quality, effectiveness and efficiency of SOT in order to support patients, health care professionals and policy makers with informed decision-making.Implement a bio-bank sampling scheme to integrate biological and clinical information.Reflect the complexity of the post-transplant patient care in an appropriate data model and integrate this complexity into research hypothesis and methodology.Collect selected psychosocial and behavioral data at time of listing and during follow-up.Systematically capture relevant infectious diseases episodes.Record and periodically update specific risk profiles to reflect changes in disease- and treatment status.Assess determinants of poor short- or long-term outcome and allow studying alternative pathways that contribute to the understanding of patient – and allograft survival [6, 7, 9–11]. …”

“…Assess determinants of poor short- or long-term outcome and allow studying alternative pathways that contribute to the understanding of patient – and allograft survival [6, 7, 9–11]. …”